Pharmaceutical

Advanz Pharma’s liver disease drug pulled from European market after court hearing

This latest update comes after Advanz secured a suspension of the European Commission’s original revocation in September 2024.

Nov 29, 2024 - 06:00
Advanz Pharma’s liver disease drug pulled from European market after court hearing
This latest update comes after Advanz secured a suspension of the European Commission’s original revocation in September 2024.
Read the original article

Tags:

Previous Article

Trump 2.0 spells global change in pharmaceutical regulation, funding and investment

Next Article

Kronos Bio announces interim CEO and workforce cuts of 83%

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Study finds supplements of amino acid taurine slow aging in mice and monkeys

STAT+: Study finds supplements of amino acid taurine sl...

Jun 8, 2023

Advancing parenteral packaging production for the future of pharmaceuticals

Advancing parenteral packaging production for the futur...

May 2, 2023

US FDA approves Krystal Biotech’s Vyjuvek for DEB

US FDA approves Krystal Biotech’s Vyjuvek for DEB

May 22, 2023